Laprophan Turns to the Stock Market to Strengthen Its Equity Capital
Laprophan: A New Chapter in Development with Its Introduction to the Casablanca Stock Exchange
The Moroccan pharmaceutical group Laprophan is entering a new phase of its development with its upcoming introduction to the Casablanca Stock Exchange. Through an operation that could reach 2.22 billion dirhams, the laboratory aims to strengthen its equity base, finance its external growth strategy, and solidify its positioning in both national and international markets. Subscriptions are open from November 9 to November 17, 2026, at a price of 341 dirhams per share.
A Fundraising of Nearly 1.4 Billion Dirhams
The operation comprises two distinct components. The first involves a capital increase through the issuance of 4,105,500 new shares, totalling approximately 1.40 billion dirhams, premium included. These resources will be directly injected into the company to reinforce its financial structure and support its development projects.
The second component concerns the sale of 2,412,200 existing shares held by MC IV Pharma and MC IV Morocco. This operation represents a maximum amount of 822.56 million dirhams, which will be allocated to the selling shareholders and will not constitute additional financial contributions for Laprophan.
In total, 6,517,700 shares are being offered to the public. Following the operation, these shares will represent 37.64% of the group’s capital and voting rights.
External Growth at the Heart of Strategy
Beyond reinforcing its equity, Laprophan intends to mobilize resources from this operation to accelerate its growth and pursue its acquisition strategy. The group aims to achieve a larger critical size in a pharmaceutical sector marked by international competition and increasing industrial capacity needs.
Among the contemplated operations is the acquisition of Corporate Investment Holding, the parent company of Polymedic laboratory. This acquisition, which remains subject to necessary regulatory approvals, is one of the main avenues identified for utilizing the new capital. According to the management’s presentation, nearly 90% of the funds raised in the capital increase could be dedicated to this operation.
This focus aligns with the continuity of acquisitions made in recent years, particularly the integration of Amanys Pharma and Botanic Pharma in Morocco, as well as the group’s expansion in Switzerland through Rivopharm.
An Industrial Group Present on Five Continents
Founded in 1949, Laprophan has gradually expanded its activities beyond its historical market. The group claims commercial presence in about fifty countries and operates four production sites located in Morocco and Switzerland, totaling 76,500 square meters of industrial space.
Its organization covers multiple stages of the pharmaceutical chain, from research and development to manufacturing and marketing of medicines. The laboratory also holds more than 1,300 marketing authorizations and employs nearly 1,450 people, according to data shared as part of its stock market introduction.
New Visibility in the Financial Market
Laprophan’s arrival at the Casablanca Stock Exchange is expected to enhance its visibility among investors and economic partners, while facilitating access to market financing.
For investors, this operation presents an opportunity to position themselves in a Moroccan pharmaceutical group committed to an industrial and international expansion strategy. The evolution of its results, the realization of the announced acquisitions, and their successful integration will be critical factors in assessing the success of this new phase of growth.
Through this stock market introduction, Laprophan aspires to consolidate its financial resources and continue its transformation into a pharmaceutical group of international stature.
